Advanced organoids reveal new pathways for spinal cord repair
Original story from Northwestern University (IL, USA).
Northwestern University scientists have developed the most advanced human spinal cord organoid model to date, enabling the study of spinal cord injuries and testing of a promising regenerative therapy. The study used lab-grown spinal cord organoids derived from stem cells to replicate key effects of spinal cord injuries, such as cell death, inflammation, and glial scarring, which blocks nerve regeneration.
When treated with “dancing molecules,” a therapy previously shown to reverse paralysis in animals, the injured organoids exhibited significant neurite outgrowth and reduced glial scarring. These results bolster hopes that the therapy, which recently received Orphan Drug Designation from the FDA, could improve outcomes for spinal cord injury patients.
“Organoids allow us to test therapies in human tissue without clinical trials,” said senior author Samuel Stupp, who developed the therapy. “After applying our therapy, the glial scar faded significantly, and neurites grew, resembling axon regeneration seen in animals. This validates the therapy’s potential for humans.”
Stupp, a pioneer in regenerative medicine, is a professor at Northwestern and directs the Center for Regenerative Nanomedicine. The study’s first author, Nozomu Takata, is a research assistant professor at Northwestern’s Feinberg School of Medicine.
Organoids: a breakthrough model
Organoids, miniature versions of human organs grown from stem cells, mimic the structure and function of real tissues. Stupp’s spinal cord organoids, grown over months to include neurons, astrocytes and microglia (immune cells), represent a significant advancement in modeling spinal cord injuries. The inclusion of microglia allowed the organoids to simulate inflammatory responses, making them a more accurate model.
“We were the first to introduce microglia into spinal cord organoids,” Stupp said. “This makes our model more realistic and effective for studying injury responses.”
Dancing molecules: a revolutionary therapy
First introduced in 2021, the dancing molecules therapy uses supramolecular motion to repair tissues and reverse paralysis. Injected as a liquid, the therapy forms a nanofiber scaffold that mimics the spinal cord’s extracellular matrix. By fine-tuning molecular motion, the therapy enhances interactions with cellular receptors, promoting regeneration.
In animal studies, a single injection helped mice regain mobility within four weeks. Faster-moving molecules showed greater therapeutic efficacy, highlighting the importance of molecular motion.
Testing the therapy
To model spinal cord injuries, the team induced two types of damage in the organoids: lacerations (simulating surgical wounds) and compressive contusions (mimicking trauma from accidents). Both injuries caused cell death and glial scarring, replicating real spinal cord injuries. When treated with dancing molecules, the therapy reduced inflammation, diminished scarring, and promoted neurite growth, including axons, which are critical for restoring neural communication and reversing paralysis.
Future directions
Stupp’s team plans to develop more advanced organoids to model chronic injuries with stubborn scar tissue. They also aim to create personalized therapies using a patient’s stem cells to avoid immune rejection. “This therapy’s success lies in its molecular motion,” Stupp said. “It’s a vivid demonstration of how supramolecular motion can drive regeneration.”
This article has been republished from the following materials. Material may have been edited for length and house style. For further information, please contact the cited source. Our press release publishing policy can be accessed here.